Have a feature idea you'd love to see implemented?
Let us know!
FENC Fennec Pharmaceuticals Inc
Price (delayed)
$6.275
Market cap
$172.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.04
Enterprise value
$161.6M
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation
Highlights
The quick ratio has soared by 65% YoY
The equity has soared by 51% YoY
The company's EPS has shrunk by 140% QoQ but it has surged by 95% YoY
Fennec Pharmaceuticals's net income has plunged by 106% from the previous quarter but it has soared by 99% YoY
FENC's debt is up by 20% year-on-year
The gross margin has contracted by 2.2% from the previous quarter
Key stats
What are the main financial stats of FENC
Market
Valuations
Earnings
Shares outstanding
27.43M
Market cap
$172.14M
Enterprise value
$161.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.48
EV/EBIT
42.63
EV/EBITDA
35.4
EV/Sales
3.27
Revenue
$49.35M
Gross profit
$46.15M
Net income
-$227,000
EBIT
$3.79M
EBITDA
$4.57M
Free cash flow
$23.59M
Per share
Balance sheet
Liquidity
EPS
-$0.04
EPS diluted
-$0.1
Free cash flow per share
$0.86
Book value per share
-$0.19
Revenue per share
$1.8
TBVPS
$2.15
Total assets
$58.92M
Total liabilities
$64.09M
Debt
$29.78M
Equity
-$5.17M
Working capital
$50.53M
Debt to equity
-5.76
Current ratio
7.8
Quick ratio
7.16
Net debt/EBITDA
-2.31
Margins
Efficiency
Dividend
EBITDA margin
9.3%
Gross margin
93.5%
Net margin
-0.5%
Operating margin
3.4%
Return on assets
-0.4%
Return on equity
N/A
Return on invested capital
9.7%
Return on capital employed
7.4%
Return on sales
7.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FENC stock price
How has the Fennec Pharmaceuticals stock price performed over time
Intraday
1.37%
1 week
7.45%
1 month
3.89%
1 year
-45.91%
YTD
-44.07%
QTD
25.5%
Financial performance
How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$49.35M
Gross profit
$46.15M
Operating income
$1.68M
Net income
-$227,000
Gross margin
93.5%
Net margin
-0.5%
The operating income has soared by 110% YoY but it has shrunk by 71% QoQ
FENC's net margin has dropped by 107% since the previous quarter but it has surged by 100% year-on-year
Fennec Pharmaceuticals's net income has plunged by 106% from the previous quarter but it has soared by 99% YoY
Fennec Pharmaceuticals's operating margin has soared by 103% YoY but it has plunged by 72% from the previous quarter
Growth
What is Fennec Pharmaceuticals's growth rate over time
Valuation
What is Fennec Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.48
EV/EBIT
42.63
EV/EBITDA
35.4
EV/Sales
3.27
The company's EPS has shrunk by 140% QoQ but it has surged by 95% YoY
The equity has soared by 51% YoY
The P/S is 49% lower than the last 4 quarters average of 6.7
Efficiency
How efficient is Fennec Pharmaceuticals business performance
The return on invested capital has surged by 117% year-on-year but it has dropped by 54% since the previous quarter
The company's return on sales has surged by 106% YoY but it fell by 50% QoQ
The return on assets has dropped by 105% since the previous quarter but it has surged by 100% year-on-year
Dividends
What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FENC.
Financial health
How did Fennec Pharmaceuticals financials performed over time
The total assets is 8% less than the total liabilities
Fennec Pharmaceuticals's total liabilities has soared by 117% YoY
The quick ratio has soared by 65% YoY
The company's debt to equity has shrunk by 145% YoY but it has surged by 74% QoQ
The equity has soared by 51% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.